Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Annexon Biosciences < Previous 1 2 Next > Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) September 16, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress September 09, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio September 03, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Biosciences to Participate in Upcoming September Investor Conferences August 29, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) August 16, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones August 12, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy August 05, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) July 16, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting July 11, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting June 25, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting June 18, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) June 17, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Announces Pricing of $125 Million Underwritten Public Offering June 05, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Announces Proposed Public Offering of Common Stock June 04, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome June 04, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data June 03, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) May 16, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones May 13, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Biosciences to Present at the Bank of America Health Care Conference May 09, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting May 07, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting May 01, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) April 16, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones March 26, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) March 18, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference February 27, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach February 21, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) February 20, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases January 07, 2024 From Annexon Biosciences Via GlobeNewswire Tickers ANNX Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 27, 2023 From Annexon Biosciences Via GlobeNewswire Tickers ANNX < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.